Sandoz, a global leader in generic and biosimilar medicines, has introduced the OMNITROPE 15mg biosimilar growth hormone in Egypt to address short stature, a condition affecting 17% of Egyptian children. This initiative aligns with Egypt’s Vision 2030 to enhance public health and workforce productivity. The introduction of this treatment is a significant step towards improving the quality of life for children with growth disturbances.
The effectiveness of growth hormone treatment in improving physical, social, psychological, and environmental aspects of life has been underscored by research conducted at the Suez Canal University in Egypt. Short stature, diagnosed in children significantly below average height for their age, can be attributed to genetic factors or underlying health conditions. Studies have shown that geographical variations and genetic predispositions play crucial roles in the prevalence of short stature.
A cross-sectional study involving 33,150 Egyptian children revealed that 17% had short stature, with familial and constitutional factors contributing significantly. Growth hormone treatment is crucial for children and adolescents affected by growth disturbances, as it can positively impact their final height outcomes. The proper administration of growth hormone during the growth plate fusion stage is essential to achieve a normal adult height.
Ensuring the availability of growth hormone has been a challenge, but efforts are underway to secure a continuous supply for uninterrupted treatment. The introduction of the OMNITROPE 15mg concentration aims to meet the increasing demand for growth hormones in Egypt, aligning with global scientific standards. This development reflects the commitment of the Egyptian medical community to provide advanced treatment solutions for patients in need.
Sandoz’s commitment to developing affordable biosimilars for high-quality biologics has led to the approval of OMNITROPE by regulatory bodies like the US FDA and the European Medicines Agency. The company has established a post-marketing surveillance program to monitor the safety of its products over time. This initiative not only expands treatment options in Egypt but also supports the national goal of sustainable development outlined in Egypt Vision 2030.
By introducing the OMNITROPE growth hormone in Egypt, Sandoz aims to support the Egyptian government’s efforts to reduce the prevalence of short stature among children. This initiative is part of a broader strategy to improve public health, build a more productive workforce, and provide comprehensive care for patients in need. Sandoz’s long-standing commitment to pioneering access for patients underscores its dedication to making healthcare more accessible and affordable worldwide.
